Blood test may predict breast cancer treatment success

NCT ID NCT02743910

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study investigates whether tumor DNA found in the blood (called plasma tumor DNA or ptDNA) can predict how well breast cancer responds to chemotherapy given before surgery. Researchers will collect blood samples from 228 people with early-stage, high-risk breast cancer (HER2-positive or triple-negative) at several time points before, during, and after treatment. The goal is to see if the absence of ptDNA after chemotherapy accurately indicates that no cancer remains at surgery, and whether ptDNA levels can forecast long-term outcomes like cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this approach could help doctors quickly tell whether a breast cancer treatment is working, potentially guiding more personalized therapy.
What could go wrong
This is an observational study, not a treatment trial. The test may not accurately predict outcomes for all patients, and results may not change current care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.